These results suggest that co-targeting ICOS and CD28 is a relevant strategy to suppress autoimmune responses and a Phase II clinical trial (NCT04835441) is ongoing to investigate the efficacy of the drug in SLE. The gene discussed is ICOS; the disease is systemic lupus erythematosus.